Drug intelligence / Profile preview

anti-whitlow monoclonal antibody

Development stage
Unknown
Lead developer
Fred Hutchinson Cancer Center
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Parenteral
01

Overview

The anti-whitlow monoclonal antibody is a novel biologic tool developed to target the Whitlow linker peptide, a 15-amino acid sequence (typically (Gly4Ser)3) frequently incorporated into the single-chain variable fragments (scFvs) of chimeric antigen receptor (CAR) constructs. Developed by a collaborative team at the Fred Hutchinson Cancer Center and the University of Washington, these antibodies serve as a universal detection reagent for CAR T-cells, independent of their specific antigen targets (such as CD19, BCMA, or CD33). The antibody is applicable in flow cytometry for monitoring CAR T-cell persistence in blood, immunohistochemistry for spatial characterization in tissues, and manufacturing processes for the selective enrichment of CAR-expressing cells. Its ability to bind the linker framework makes it a versatile asset for both preclinical research and clinical translational studies.

Other names
anti-Whitlow mAbanti-Whitlow linker antibody

Beyond the preview

Go deeper on anti-whitlow monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-whitlow monoclonal antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call